Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
Antibodies, Viral
/ blood
Betacoronavirus
/ immunology
Blood Component Removal
/ methods
Blood Donors
COVID-19
Coronavirus Infections
/ blood
Donor Selection
/ standards
Humans
Immune Sera
/ adverse effects
Immunization, Passive
/ adverse effects
Pandemics
Pneumonia, Viral
/ blood
Product Labeling
Risk
SARS-CoV-2
COVID-19 Serotherapy
COVID-19
Immune plasma
Journal
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
pubmed:
14
6
2020
medline:
29
8
2020
entrez:
14
6
2020
Statut:
ppublish
Résumé
Passive immunotherapy with plasma derived from patients convalescent from SARS-CoV-2 infection can be a promising approach in the treatment of COVID-19 patients. It is important that Blood Establishments are prepared to satisfy requests for immune plasma by defining the requirements applicable to plasma donors and the standards for preparation, qualification, storage, distribution and control of use of the product. This position paper is aimed to give recommendations on biological characteristics of a plasma preparation from convalescent donors and to support the evaluation of this therapeutic approach in more rigorous investigations.
Identifiants
pubmed: 32532691
pii: S1473-0502(20)30112-9
doi: 10.1016/j.transci.2020.102817
pmc: PMC7239775
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immune Sera
0
Types de publication
Journal Article
Practice Guideline
Review
Langues
eng
Pagination
102817Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The Authors declare no conflicts of interest.
Références
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Clin Microbiol Infect. 2004 Jul;10(7):676-8
pubmed: 15214887
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489
JAMA. 2020 Apr 28;323(16):1561-1562
pubmed: 32219429
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Springerplus. 2015 Nov 19;4:709
pubmed: 26618098
J Immunol. 2001 Oct 1;167(7):3910-8
pubmed: 11564809
Intensive Care Med. 2017 Feb;43(2):192-199
pubmed: 27812731